Research Analysts Set Expectations for DBVT Q2 Earnings

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Stock analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for DBV Technologies in a research report issued on Thursday, June 26th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings per share of ($0.13) for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share. Lifesci Capital also issued estimates for DBV Technologies' Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.62) EPS and FY2026 earnings at ($0.29) EPS.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. The company had revenue of $0.51 million for the quarter.

DBVT has been the subject of a number of other research reports. HC Wainwright lifted their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 5th. JMP Securities reiterated a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a report on Thursday. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a research note on Thursday, May 29th. Citigroup restated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. Finally, Wall Street Zen upgraded shares of DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, DBV Technologies has a consensus rating of "Moderate Buy" and an average price target of $14.75.

DBV Technologies Price Performance

DBVT opened at $9.19 on Monday. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The stock has a market cap of $251.58 million, a P/E ratio of -1.87 and a beta of -0.63. The stock's 50 day simple moving average is $9.24 and its 200 day simple moving average is $6.32.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.